OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
694257

Sophia Holdings Co Ltd

Drug RetailersVerified

Sophia Holdings Co Ltd has a liquidity position that is characterized by a current ratio of 1.54, indicating that the company has sufficient current assets to cover its current liabilities. The company's cash and equivalents amount to 2,813,879,000 JPY, which is partially offset by long-term debt of 3,229,387,000 JPY, resulting in a negative net cash position. This suggests that the company may need to manage its debt obligations carefully to maintain liquidity. In terms of profitability, Sophia Holdings Co Ltd reported a net loss of 155,830,000 JPY and an operating loss of 69,097,000 JPY, indicating a challenging financial performance. The return on equity (ROE) is -5.55%, and the return on assets (ROA) is -1.87%, both of which are below the industry median for drug retailers. These metrics suggest that the company is not generating returns that meet industry expectations. The company's revenue is concentrated in the drug retailing segment, with no disclosed geographic diversification in the provided data. This lack of geographic diversification could expose the company to regional economic fluctuations and regulatory changes that may impact its operations and revenue. Looking at the growth trajectory, the company's recent financial performance shows a decline in profitability, with a net loss and operating loss reported. The capital expenditure of -32,102,000 JPY indicates that the company is not investing heavily in new projects or infrastructure, which may affect its long-term growth potential. The operating cash flow of 775,335,000 JPY provides some positive cash generation, but it is not sufficient to offset the net loss and debt obligations. The risk assessment for Sophia Holdings Co Ltd indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 1.15 suggests a moderate level of leverage, which could increase financial risk if interest rates rise or if the company's earnings decline further. The key flag of negative net cash after subtracting total debt highlights the need for careful debt management to avoid liquidity constraints. Recent events and filings do not provide specific details on new initiatives or strategic changes for Sophia Holdings Co Ltd. The company's financial performance and risk profile suggest that it may need to focus on improving profitability and managing its debt to ensure long-term stability.

30-day price · 6942(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanySophia Holdings Co Ltd
Ticker6942.T
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryDrug Retailers
AI analysis

Business. Sophia Holdings Co Ltd operates in the drug retailing industry, primarily generating revenue through the sale of pharmaceuticals and related products.

Classification. Sophia Holdings Co Ltd is classified under the Consumer Non-Cyclicals economic sector, Food & Drug Retailing business sector, and Drug Retailers industry, with a classification confidence of 0.92.

Sophia Holdings Co Ltd has a liquidity position that is characterized by a current ratio of 1.54, indicating that the company has sufficient current assets to cover its current liabilities. The company's cash and equivalents amount to 2,813,879,000 JPY, which is partially offset by long-term debt of 3,229,387,000 JPY, resulting in a negative net cash position. This suggests that the company may need to manage its debt obligations carefully to maintain liquidity. In terms of profitability, Sophia Holdings Co Ltd reported a net loss of 155,830,000 JPY and an operating loss of 69,097,000 JPY, indicating a challenging financial performance. The return on equity (ROE) is -5.55%, and the return on assets (ROA) is -1.87%, both of which are below the industry median for drug retailers. These metrics suggest that the company is not generating returns that meet industry expectations. The company's revenue is concentrated in the drug retailing segment, with no disclosed geographic diversification in the provided data. This lack of geographic diversification could expose the company to regional economic fluctuations and regulatory changes that may impact its operations and revenue. Looking at the growth trajectory, the company's recent financial performance shows a decline in profitability, with a net loss and operating loss reported. The capital expenditure of -32,102,000 JPY indicates that the company is not investing heavily in new projects or infrastructure, which may affect its long-term growth potential. The operating cash flow of 775,335,000 JPY provides some positive cash generation, but it is not sufficient to offset the net loss and debt obligations. The risk assessment for Sophia Holdings Co Ltd indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 1.15 suggests a moderate level of leverage, which could increase financial risk if interest rates rise or if the company's earnings decline further. The key flag of negative net cash after subtracting total debt highlights the need for careful debt management to avoid liquidity constraints. Recent events and filings do not provide specific details on new initiatives or strategic changes for Sophia Holdings Co Ltd. The company's financial performance and risk profile suggest that it may need to focus on improving profitability and managing its debt to ensure long-term stability.
Key takeaways
  • Sophia Holdings Co Ltd is experiencing a net loss and operating loss, indicating a challenging financial performance.
  • The company's liquidity position is moderate, with a current ratio of 1.54 and a negative net cash position after subtracting total debt.
  • The return on equity and return on assets are below industry medians, suggesting underperformance relative to peers.
  • The company's revenue is concentrated in the drug retailing segment, with no disclosed geographic diversification.
  • The company's capital expenditure is negative, indicating a lack of investment in new projects or infrastructure.
  • # RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$2.25B
Gross profit$852.9M
Operating income-$69.1M
Net income-$155.8M
R&D
SG&A
D&A
SBC
Operating cash flow$775.3M
CapEx-$32.1M
Free cash flow
Total assets$8.34B
Total liabilities$5.53B
Total equity$2.81B
Cash & equivalents$2.81B
Long-term debt$3.23B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$11.38B$596.2M$501.9M$939.2M
FY-3$11.78B$877.7M$613.3M$911.5M
FY-2$9.42B$195.0M$21.1M$416.1M
FY-1$9.03B$403.3M$230.1M$381.8M
FY0$8.36B$344.8M$95.3M$171.6M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$8.61B$1.39B$2.12B
FY-3$8.60B$2.00B$2.34B
FY-2$7.40B$2.03B$2.02B
FY-1$8.34B$2.81B$2.81B
FY0$7.46B$3.03B$2.75B
PeriodOCFCapExFCFSBC
FY-4$1.23B-$26.0M$939.2M
FY-3$1.07B-$139.1M$911.5M
FY-2$411.1M-$37.5M$416.1M
FY-1$775.3M-$32.1M$381.8M
FY0$261.4M-$98.5M$171.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$2.25B-$69.1M-$155.8M
FQ-6$2.07B$240.6M$74.4M
FQ-5$2.11B$59.6M$11.4M
FQ-4$2.14B$469.3M$148.4M
FQ-3
FQ-2$1.98B$25.6M$9.7M
FQ-1$2.03B-$27.9M-$9.3M
FQ0$2.14B$81.1M$36.1M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$8.34B$2.81B$2.81B
FQ-6$7.55B$3.36B$2.97B
FQ-5$7.43B$3.28B$2.87B
FQ-4$7.49B$3.54B$2.82B
FQ-3$7.46B$3.03B$2.75B
FQ-2$6.94B$3.04B$2.25B
FQ-1$6.99B$3.03B$2.12B
FQ0$6.91B$3.06B$1.84B
PeriodOCFCapExFCFSBC
FQ-7$775.3M-$32.1M
FQ-6
FQ-5$124.7M-$37.3M
FQ-4
FQ-3$261.4M-$98.5M
FQ-2
FQ-1-$14.5M-$63.3M
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.81B
Net cash-$415.5M
Current ratio1.5
Debt/Equity1.1
ROA-1.9%
ROE-5.5%
Cash conversion-5.0%
CapEx/Revenue-1.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 184 companies
Metric6942Activity
Op margin-3.1%3.1% medp25 1.2% · p75 6.8%bottom quartile
Net margin-6.9%2.0% medp25 0.7% · p75 4.1%bottom quartile
Gross margin38.0%26.1% medp25 17.2% · p75 32.0%top quartile
CapEx / revenue-1.4%-2.5% medp25 -4.6% · p75 -1.4%above median
Debt / equity115.0%56.0% medp25 16.8% · p75 121.1%above median
Observations
IR observations
Last actual EPS20.79 JPY
Last actual revenue8,360,190,000 JPY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 04:10 UTC#c2d23f4d
Market quoteclose JPY 1290.00 · shares 0.00B diluted
no public URL
2026-05-09 04:10 UTC#41ef49bd
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 02:34 UTCJob: 65258cde